Want to see ACOG full AI Analyst Report?
ACOG Stock Chart & Stats
$6.94
<$0.01(0.02%)
At close: 4:00 PM EST
$6.94
<$0.01(0.02%)
Day’s Range― - ―
52-Week Range$4.50 - $11.54
Previous Close$5.43
Volume265.46K
Average Volume (3M)87.53K
Market Cap
$171.80M
Enterprise Value$49.50M
Total Cash (Recent Filing)$54.25M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Aug 26, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding21,774,103
10 Day Avg. Volume111,240
30 Day Avg. Volume87,535
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.84
Price to Sales (P/S)11.24
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue4.57
Enterprise Value/Gross Profit5.42
Enterprise Value/Ebitda-1.84
Forecast
1Y Price Target
$15.00Price Target Upside116.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.35
Revenue Forecast (FY)$22.77M
Bulls Say, Bears Say
Bulls Say
High Gross Margin With Strong Revenue ScalingSustained ~87% gross margin alongside ~5.9x revenue growth vs prior period indicates product economics that can support operating leverage as commercial scale expands. Durable high margins mean incremental revenue largely flows to cover fixed R&D and sales investments, aiding a path to profitability if growth continues.
Debt-free Balance Sheet And Multi‑month Cash RunwayA debt-free balance sheet with sizable equity and cash provides structural financial flexibility to fund clinical programs and commercialization without near-term refinancing risk. This reduces solvency risk and gives management optionality to prioritize R&D and payer engagement through upcoming catalysts.
Early Commercial Traction And Repeat UtilizationSequential revenue growth, rising bottles dispensed, growing active prescribers and high repeat prescription rates demonstrate real-world demand and prescriber retention. These structural adoption signals support sustainable revenue scaling, stronger bargaining power with payers, and a clearer path to operating leverage over time.
Bears Say
Significant Cash BurnLarge and ongoing negative operating and free cash flows imply persistent reliance on external financing unless revenue growth accelerates materially or spending is reduced. Over multiple quarters this cash burn can dilute shareholders or force strategic tradeoffs between commercialization pace and clinical investment.
Deep Negative Profitability And ROE ErosionVery negative net margins and sharply negative returns on equity reflect that operating costs currently far exceed revenues. This structural loss-making posture will continue to erode equity and investor optionality unless the company achieves sustained revenue scale or materially improves operating leverage.
Payer Implementation Headwinds Limit AccessDespite broad PBM agreements, low downstream plan activation constrains patient access and monetization. This structural fricton creates a bottleneck to converting commercial traction into durable revenue growth and heightens dependence on payer negotiations and real-world evidence to expand coverage.
Alpha Cognition Inc News
ACOG FAQ
What was Alpha Cognition Inc’s price range in the past 12 months?
Alpha Cognition Inc lowest stock price was $4.50 and its highest was $11.54 in the past 12 months.
What is Alpha Cognition Inc’s market cap?
Alpha Cognition Inc’s market cap is $171.80M.
When is Alpha Cognition Inc’s upcoming earnings report date?
Alpha Cognition Inc’s upcoming earnings report date is Aug 26, 2026 which is in 52 days.
How were Alpha Cognition Inc’s earnings last quarter?
Alpha Cognition Inc released its earnings results on May 14, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.387 by $0.067.
Is Alpha Cognition Inc overvalued?
According to Wall Street analysts Alpha Cognition Inc’s price is currently Undervalued.
Does Alpha Cognition Inc pay dividends?
Alpha Cognition Inc does not currently pay dividends.
What is Alpha Cognition Inc’s EPS estimate?
Alpha Cognition Inc’s EPS estimate is -0.4.
How many shares outstanding does Alpha Cognition Inc have?
Alpha Cognition Inc has 21,774,103 shares outstanding.
What happened to Alpha Cognition Inc’s price movement after its last earnings report?
Alpha Cognition Inc reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.387. Following the earnings report the stock price went up 5.986%.
Which hedge fund is a major shareholder of Alpha Cognition Inc?
Currently, no hedge funds are holding shares in ACOG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Cognition Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (116.14% Upside)
$15.00 (116.14% Upside)
Blogger Sentiment
Bullish
ACOG Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 16.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.51%
12-Months-Change
Fundamentals
Return on Equity
-54.13%
Trailing 12-Months
Asset Growth
42.46%
Trailing 12-Months
Company Description
Alpha Cognition Inc
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
ACOG Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong early commercial trajectory for ZUNVEYL with clear sequential growth in revenue (40% QoQ), accelerating prescription metrics (bottles +23% QoQ, prescriber calls +93% QoQ) and multiple near-term clinical and IP catalysts (BEACON, CONVERGE, sublingual PK, two patents to 2045). Management is deliberately investing in a 60-person commercial team, payer engagement, and real-world evidence generation to drive broader access and expects operating profitability in 2027. Offsetting these positives are meaningful near-term challenges: increased net losses and operating spend, cash decline, limited downstream PBM implementation (~16% of book), and reliance on upcoming data to expand payer coverage. Overall the call was upbeat and progressing toward commercialization scale, but the company remains in an investment phase with execution and payer adoption as key near-term risks.View all ACOG earnings summariesACOG Stock 12 Month Forecast
Average Price Target
$15.00
▲(116.14% Upside)
Technical Analysis
Ownership Overview
19.00% Insiders
0.06% Mutual Funds
46.29% Other Institutional Investors
34.65% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---